NCT03077750已完成2 期
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase II Study to Evaluate the Efficacy, Tolerability, and Safety of VBP-245 in Pediatric Subjects for the Treatment of Molluscum Contagiosum
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 110
- 试验地点
- 3
- 主要终点
- Reduction in number of MCV lesions
研究概览
简要总结
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase II Study to Evaluate the Efficacy, Tolerability, and Safety of Topical VBP-245 in Pediatric Subjects for the Treatment of Molluscum Contagiosum (VBP-245-MCV).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 2 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must meet all of the following inclusion criteria:
- •Males or females aged 2-18 years at screening;
- •MC diagnosed by a general physician, dermatologist or pediatrician who refers it and treatable by a topical agent;
- •Individuals with at least 1, but not exceeding 15 molluscum selected in designated treatment area:
- •Individuals whose treatment area is located anywhere on the body except for the following prohibited areas which include: eye area (including eyelids), lips, mouth cavity, nasal cavity, inner ear, palms of the hands, soles of the feet or the anogenital area;
- •Free from any systemic or dermatologic disorder that, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse advents;
- •Free from atopic dermatitis in the treatment area that, in the opinion of the investigator, will potentially get inflamed or irritated during the course of treatment;
- •Parent or guardian able to give appropriate informed consent as determined by the approving institutional review board (IRB);
- •Individuals who are generally in good health as determined by the investigator;
- •Willingness and ability of parent or guardian to read, understand, and sign the IRB-approved informed consent form after the nature of the study has been fully explained and questions have been answered;
- •Individuals who are willing to not start any new products OTC or prescription treatments and discontinue any treatment the investigator feels may interfere with the evaluation of the test products;
- •Individuals who are willing to avoid using cosmetic products, creams, salves, or ointments to the treatment area(s);
- •Individuals who are willing and able to thoroughly follow the product use instructions, attend all the scheduled visits and successfully complete the study;
- •Individuals who are willing and able to not begin any office based treatments for the duration of the study;
- •Female subjects of childbearing age with negative pregnancy test at the enrolment time in the study;
- •Female subjects who are not breastfeeding at the enrolment time in the study;
- •Female subjects that do not intend to become pregnant during their participation in the study;
- •Female subjects with reproductive potential must agree to practice medically acceptable form of birth control during the study • Medically acceptable forms of birth control that may be used by the subject and/or his/her partner include: o Established use of hormonal methods of contraception (oral, injected, implanted, patch or vaginal ring) Barrier methods of contraception with spermicide: condom or occlusive cap (diaphragm or cervical/Vault caps) with a spermicidal foam/gel/film/cream or suppository; o Intrauterine divide (IUD) or intrauterine system (IUS); o Surgical sterilization (vasectomy, tubal occlusion, bilateral salpingectomy); Abstinence from heterosexual intercourse; when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (calendar, ovulation, symptothermal, post ovulation methods) and withdrawal are NOT acceptable methods of contraception
排除标准
- •Subjects meeting the following exclusion criteria will be excluded from the study:
- •Mentally incompetent or unable or not willing to give written informed consent via parent or guardian or meet study requirements
- •Known history of hypersensitivity to topical povidone-iodine
- •Significant atopic dermatitis surrounding the molluscum contagiosum lesions as judged by the investigator
- •Individual lesions greater than 5mm in diameter
- •Pregnant, breastfeeding or unwilling to undergo an acceptable form of contraception for the duration of the study;
- •Molluscum lesions located on the eye area (including eyelids), lips, mouth cavity, nasal cavity, inner ear, palms of the hands, soles of the feet or the anogenital area;
- •Have participated in an investigational trial within 30 days prior to enrollment;
- •Have required or will require systemic intake of immunosuppressive or immunomodulatory medication (including oral or parenteral corticosteroids) within 30 days prior to enrollment or during the course of the study.
- •Have any uncontrolled current infection;
- •Female subject who is pregnant, lactating planning to become pregnant, or is breastfeeding;
- •Have any chronic or acute medical condition that, in the opinion of the investigator, may interfere with the study results or place the subject at undue risk (such as an immunodeficiency or relevant genetic syndrome);
- •Have any active malignancy or are undergoing treatment for any malignancy other than non-melanoma skin cancer; Subjects viewed by the Principal Investigator as not being able to complete the study -
研究组 & 干预措施
Vehicle
Placebo Comparator
Vehicle Gel Applied to Affected Area BID
干预措施: Vehicle (Drug)
VBP-245
Experimental
VBP-245 Topical Gel Applied to Affected Area BID
干预措施: VBP-245 Topical Gel (Drug)
结局指标
主要结局
Reduction in number of MCV lesions
时间窗: 60 days
Number of lesions from baseline to day 60 will be counted and the reduction in number will be recorded.
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque PsoriasisPlaque PsoriasisNCT03837743Durect25
已完成
2 期
Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of AcneAcne VulgarisPropionibacterium AcnesAcneNCT00211497BioWest Therapeutics Inc255
终止
2 期
A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque PsoriasisPlaque PsoriasisNCT06380907Zai Lab (Hong Kong), Ltd.65
已完成
2 期
A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203)Plaque PsoriasisNCT03065556Therapeutics, Inc.89
已完成
2 期
A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular DementiaAlzheimer's Disease or Vascular DementiaNCT02886494Charsire Biotechnology Corp.80